Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of ALZ-801 in Early Alzheimer's Disease with APOE4/4 Genotype
2020-005755-20Phase 3Completed
- Sponsor
- Alzheon, Inc.
- Start
- Apr 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing ALZ-801 with Placebo (2 arms). Started Apr 2021; status: completed.
02
Drugs
valiltramiprosate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2020-005755-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005755-20.